Evidence map›Paper›PMID 26980105›Full record

ArticleEuropean journal of human genetics : EJHG2016

Responsible implementation of expanded carrier screening.

Lidewij Henneman, Pascal Borry, Davit Chokoshvili, Martina C Cornel, Carla G van El, Francesca Forzano, Alison Hall, Heidi C Howard, Sandra Janssens, Hülya Kayserili and 7 more

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 147 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
147citing papers in PubMed, 3 pooled it
27.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

147 citing papers in PubMed, 3 syntheses or guidelines pooled it, 325 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Review
  9. Article
  10. The clinical utility of carrier screening.NPJ genomic medicine · 2026
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

87 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 12 institutions in 8 countries.

Lidewij HennemanDepartment of Clinical Genetics, Section Community Genetics and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, The Netherlands.
Pascal BorryCentre for Biomedical Ethics and Law, University of Leuven, Leuven, Belgium.
Davit ChokoshviliCentre for Biomedical Ethics and Law, University of Leuven, Leuven, Belgium.
Martina C CornelDepartment of Clinical Genetics, Section Community Genetics and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, The Netherlands.
Carla G van ElDepartment of Clinical Genetics, Section Community Genetics and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, The Netherlands.
Francesca ForzanoMedical Genetics Unit, Ospedali Galliera, Genova, Italy.
Alison HallPHG Foundation, Cambridge, UK.
Heidi C HowardCentre for Research Ethics and Bioethics, Uppsala University, Uppsala, Sweden.
Sandra JanssensCentre for Medical Genetics Ghent, University Hospital Ghent, Ghent, Belgium.
Hülya KayseriliDepartment of Medical Genetics, Koç University School of Medicine (KUSoM), Istanbul, Turkey.
Phillis LakemanDepartment of Clinical Genetics, Academic Medical Center, Amsterdam, The Netherlands.
Anneke LucassenDepartment of Clinical Ethics and Law (CELS), University of Southampton and Wessex Clinical Genetic Service, Southampton, UK.
Sylvia A MetcalfeMurdoch Children's Research Institute and Department of Paediatrics, The University of Melbourne, Parkville, VIC, Australia.
Lovro VidmarClinical Institute of Medical Genetics, Ljubljana University Medical Centre, Ljubljana, Slovenia.
Guido de WertDepartment of Health, Ethics & Society, Research Schools CAPHRI and GROW, Maastricht University, Maastricht, The Netherlands.
Wybo J DondorpDepartment of Health, Ethics & Society, Research Schools CAPHRI and GROW, Maastricht University, Maastricht, The Netherlands.
Borut PeterlinClinical Institute of Medical Genetics, Ljubljana University Medical Centre, Ljubljana, Slovenia.
EMGO Institute for Health and Care Research · NLKU Leuven · BELjubljana University Medical Centre · SIMaastricht University · NLAcademic Medical Center · NLEnte Ospedaliero Ospedali Galliera · ITGhent University Hospital · BEKoç University · TRMurdoch Children's Research Institute · AUPHG Foundation · GBUniversity of Southampton · GBUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This document of the European Society of Human Genetics contains recommendations regarding responsible implementation of expanded carrier screening. Carrier screening is defined here as the detection of carrier status of recessive diseases in couples or persons who do not have an a priori increased risk of being a carrier based on their or their partners' personal or family history. Expanded carrier screening offers carrier screening for multiple autosomal and X-linked recessive disorders, facilitated by new genetic testing technologies, and allows testing of individuals regardless of ancestry or geographic origin. Carrier screening aims to identify couples who have an increased risk of having an affected child in order to facilitate informed reproductive decision making. In previous decades, carrier screening was typically performed for one or few relatively common recessive disorders associated with significant morbidity, reduced life-expectancy and often because of a considerable higher carrier frequency in a specific population for certain diseases. New genetic testing technologies enable the expansion of screening to multiple conditions, genes or sequence variants. Expanded carrier screening panels that have been introduced to date have been advertised and offered to health care professionals and the public on a commercial basis. This document discusses the challenges that expanded carrier screening might pose in the context of the lessons learnt from decades of population-based carrier screening and in the context of existing screening criteria. It aims to contribute to the public and professional discussion and to arrive at better clinical and laboratory practice guidelines.

Indexed as

HeterozygotePractice Guidelines as TopicDecision MakingEuropeGenetic CounselingGenetics, MedicalGenetic TestingHumansSocieties, Medical

Identifiers

PMID26980105
PMCPMC4867464
OpenAlexW2302294685

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.